Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

347
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
347
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.2K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.2K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Angina IV: Management01:26

Angina IV: Management

366
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
366
Angina V: Nursing Management01:20

Angina V: Nursing Management

428
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
428

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Partner Management and Counseling in Prenatal Care of Women Diagnosed with Sexually Transmitted Infections.

Sexually transmitted diseases·2026
Same author

A systematic review of explainable artificial intelligence and cardiac electrophysiological models addressing sports-related sudden cardiac death and arrest in adolescents and young adults.

NPJ digital medicine·2026
Same author

Implementation of Evidence-Based, Person-Centered Alternative Delivery Models for Cardiac Rehabilitation in a Rural and Remote Population: The Country Heart Attack Prevention (CHAP) Project.

Heart, lung & circulation·2026
Same author

COVID-19 outcomes and persistent symptoms in patients with hypertrophic cardiomyopathy: association with pre-existing cardiovascular magnetic resonance phenotype.

Heart (British Cardiac Society)·2026
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Diet-induced metabolic and faecal microbiome responses in pet dogs fed a minimally processed versus extruded kibble diet.

Frontiers in veterinary science·2026

Related Experiment Video

Updated: Feb 28, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K

Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention

Sivabaskari Pasupathy1, Rosanna Tavella1, Suchi Grover1

  • 1From Discipline of Medicine, University of Adelaide, Australia (S.P., R.T., B.R., N.E.K.P., Y.T.D., G.M., C.Z., M.A., J.D.H., J.F.B); Basil Hetzel Institute for Translational Health Research, Adelaide, Australia (S.P., R.T., B.R., N.E.K.P., I.S., T.H., A.H., C.Z., J.D.H., J.F.B); Central Adelaide Local Health Network, Australia (S.P., R.T., B.R., N.E.K.P., Y.D., G.M., I.S., T.H., A.H., C.Z., J.D.H., J.F.B); Northern Adelaide Local Health Network, Australia (G.M., C.Z., M.A., J.F.B.); Southern Adelaide Local Health Network, Australia (S.G., J.S.); Discipline of Medicine, Flinders University, Adelaide, Australia (S.G., J.S.); and South Australian Health and Medical Research Institute, Adelaide, Australia (J.S.).

Circulation
|June 22, 2017
PubMed
Summary
This summary is machine-generated.

N-acetylcysteine (NAC) combined with nitroglycerin reduced heart attack size in patients undergoing percutaneous coronary intervention. This combination therapy shows promise for improving outcomes in ST-elevation myocardial infarction patients.

Keywords:
ST elevation myocardial infarctionacetylcysteinemyocardial infarctionmyocardial reperfusion injurynitroglycerinpercutaneous coronary intervention

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.7K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.8K

Related Experiment Videos

Last Updated: Feb 28, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.7K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.8K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Contemporary ST-segment-elevation myocardial infarction (STEMI) management relies on primary percutaneous coronary intervention (PCI).
  • Ancillary therapies are being investigated to further reduce infarct size in STEMI patients undergoing PCI.
  • N-acetylcysteine (NAC), an antioxidant, potentiates nitroglycerin and is a potential ancillary therapy for STEMI.

Purpose of the Study:

  • To evaluate the efficacy of N-acetylcysteine (NAC) as an ancillary therapy in reducing infarct size in patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).

Main Methods:

  • A randomized, double-blind, placebo-controlled, multicenter trial (NACIAM) involving 112 STEMI patients undergoing primary PCI.
  • Patients received either high-dose intravenous NAC (29 g over 2 days) or placebo, both with background low-dose nitroglycerin.
  • Infarct size was assessed using early cardiac magnetic resonance imaging (CMR).

Main Results:

  • Of 75 patients who underwent early CMR, those randomized to NAC showed a 5.5% absolute reduction in infarct size compared to placebo (11.0% vs. 16.5%, P=0.02).
  • Myocardial salvage was significantly improved in the NAC group (60% vs. 27%, P<0.01).
  • Median creatine kinase areas under the curve were lower in the NAC group (22,000 IU·h vs. 38,000 IU·h, P=0.08).

Conclusions:

  • High-dose intravenous NAC combined with low-dose intravenous nitroglycerin significantly reduces infarct size in STEMI patients undergoing primary PCI.
  • The findings suggest a potential benefit of NAC as an ancillary therapy in STEMI management.
  • Further research in a larger study is warranted to confirm the impact on clinical cardiac outcomes.